Discovery of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 2-(5-(4′-Chloro-[1,1′-biphenyl]-4-yl)-4H-1,2,4-triazol-3-yl)ethan-1-amine (LK00764) for the Treatment of Psychotic Disorders

A focused in-house library of about 1000 compounds comprising various heterocyclic motifs in combination with structural fragments similar to β-phenylethylamine or tyramine was screened for the agonistic activity towards trace amine-associated receptor 1 (TAAR1). The screening yielded two closely related hits displaying EC50 values in the upper submicromolar range. Extensive analog synthesis and testing for TAAR1 agonism in a BRET-based cellular assay identified compound 62 (LK00764) with EC50 = 4.0 nM. The compound demonstrated notable efficacy in such schizophrenia-related in vivo tests as MK-801-induced hyperactivity and spontaneous activity in rats, locomotor hyperactivity of dopamine transporter knockout (DAT-KO) rats, and stress-induced hyperthermia (i.p. administration). Further preclinical studies are necessary to evaluate efficacy, safety and tolerability of this potent TAAR1 agonist for the potential development of this compound as a new pharmacotherapy option for schizophrenia and other psychiatric disorders.

[1]  N. Dedic,et al.  Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia , 2021, ACS medicinal chemistry letters.

[2]  David E. Gloriam,et al.  The G protein database, GproteinDb , 2021, Nucleic Acids Res..

[3]  O. Howes,et al.  Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies , 2021, International journal of molecular sciences.

[4]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[5]  Gregory A Ross,et al.  OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. , 2021, Journal of chemical theory and computation.

[6]  R. Gainetdinov,et al.  Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies , 2020, Pharmaceuticals.

[7]  Ruyan Wu,et al.  TAAR1 and Psychostimulant Addiction , 2020, Cellular and Molecular Neurobiology.

[8]  David S Palmer,et al.  Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics , 2020, J. Chem. Inf. Model..

[9]  N. Dedic,et al.  SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[10]  R. Gainetdinov,et al.  Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats , 2019, Neuropharmacology.

[11]  M. Hoener,et al.  Trace Amines and Their Receptors , 2018, Pharmacological Reviews.

[12]  R. Gainetdinov,et al.  Trace Amine-Associated Receptor 1 Modulates the Locomotor and Sensitization Effects of Nicotine , 2018, Front. Pharmacol..

[13]  Michele Tonelli,et al.  Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists. , 2018, European journal of medicinal chemistry.

[14]  T. Sotnikova,et al.  Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats , 2018, The Journal of Neuroscience.

[15]  M. Shahid,et al.  Pharmacology of human trace amine‐associated receptors: Therapeutic opportunities and challenges☆ , 2017, Pharmacology & therapeutics.

[16]  L. LeBrun,et al.  The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. , 2017, Journal of medicinal chemistry.

[17]  R. Gainetdinov,et al.  Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies. , 2017, European journal of medicinal chemistry.

[18]  S. Mohr,et al.  Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists. , 2016, ACS medicinal chemistry letters.

[19]  T. Sotnikova,et al.  Dopamine transporter mutant animals: a translational perspective , 2016, Journal of neurogenetics.

[20]  R. Gainetdinov,et al.  Further Insights Into the Pharmacology of the Human Trace Amine‐Associated Receptors: Discovery of Novel Ligands for TAAR1 by a Virtual Screening Approach , 2014, Chemical biology & drug design.

[21]  Stephen R. Morairty,et al.  A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight , 2013, Molecular Psychiatry.

[22]  R. Gainetdinov,et al.  Insights into the Structure and Pharmacology of the Human Trace Amine‐Associated Receptor 1 (hTAAR1): Homology Modelling and Docking Studies , 2013, Chemical biology & drug design.

[23]  Stephen R. Morairty,et al.  Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics , 2012, Biological Psychiatry.

[24]  M. Hoener,et al.  Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012. , 2012, Bioorganic & medicinal chemistry letters.

[25]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[26]  T. Sotnikova,et al.  TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity , 2011, Proceedings of the National Academy of Sciences.

[27]  T. Sotnikova,et al.  Functional interaction between Trace Amine Associated Receptor 1 (TAAR1) and dopamine D2 receptor , 2011 .

[28]  David Calkins,et al.  Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..

[29]  T. Sotnikova,et al.  Pharmacological Characterization of Membrane-Expressed Human Trace Amine-Associated Receptor 1 (TAAR1) by a Bioluminescence Resonance Energy Transfer cAMP Biosensor , 2008, Molecular Pharmacology.

[30]  Richard A. Friesner,et al.  Flexible ligand docking with Glide. , 2007, Current protocols in bioinformatics.

[31]  W. Danysz,et al.  Effects of NMDA receptor channel blockers, MK-801 and memantine, on locomotor activity and tolerance to delay of reward in Wistar−Kyoto and spontaneously hypertensive rats , 2004, Behavioural pharmacology.

[32]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[33]  Tommy Pattij,et al.  Stress-induced hyperthermia and anxiety: pharmacological validation. , 2003, European journal of pharmacology.

[34]  D. Grandy,et al.  Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. , 2001, Molecular pharmacology.

[35]  Beth Borowsky,et al.  Trace amines: Identification of a family of mammalian G protein-coupled receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Rapoport,et al.  Acylation of dibasic compounds containing amino amidine and aminoguanidine functions , 1981 .